Publication of Interim Results Delayed

RNS Number : 5433U

Allergy Therapeutics PLC

29 March 2023

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL", the "Company" or the "Group")

Publication of Interim Results Delayed

29 March 2023 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it will not publish its interim results for the six-month period to 31 December 2022 by 31 March 2023.

On 29 December 2022, the Company announced a delay in the publication of its annual report and accounts for the year to 31 June 2022 due to delays in completing the audit. Consequently, the Company's shares were suspended from trading on 3 January 2023 and remain suspended.

The Company is actively working to finalise the audit and publication of its 2022 annual report and accounts and its interim results. Allergy Therapeutics remains in active discussions regarding its funding situation and will update the market in due course.

For further information on the Company , please visit the website :   www.allergytherapeutics.com .

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.

-  ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Davide Salvi

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite, and peanut.

 

END

 

 

NORPPUPUWUPWPGR